Previous 10 | Next 10 |
Galmed (NASDAQ: GLMD ): Q1 GAAP EPS of -$0.17 beats by $0.04. More news on: Galmed Pharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
TEL AVIV, Israel , May 7, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoh...
TEL AVIV, Israel , April 30, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator, Aramchol, an oral therapy for the treatment of nonalco...
Most developers of therapies to treat nonalcoholic steatohepatitis (NASH) are under modest pressure as investors remain unimpressed with the initial announcements from The International Liver Congress in Vienna. More news on: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Enanta P...
Galmed Pharmaceuticals (NASDAQ: GLMD ) announces that it has reached "general agreement" with the FDA on key aspects of a Phase 3/4 clinical trial, ARMOR, that will support a U.S. marketing application for Aramchol (arachidyl amido cholanoic acid) in NASH patients with fibrosis. More new...
TEL AVIV, Israel , April 9, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator, Aramchol, an oral therapy for the treatment of nonalcoh...
Market Assessment Galmed ( GLMD ) is a small cap ($177M) clinical-stage biopharma developing innovative therapeutics for NASH, a chronic liver disease with high unmet medical needs. The lead investigative drug candidate, aramchol, is pharmacologically and mechanistically designed to negati...
Quick Take Genfit S.A. ( GNFT ) intends to raise $130 million in a global IPO from the sale of ADSs representing underlying ordinary shares, per an amended registration statement . The company is developing treatments for non-alcoholic steatohepatitis [NASH] conditions. GNFT expects Pha...
Galmed Pharmaceuticals Ltd. (GLMD) Q4 2018 Results Earnings Conference Call March 13, 2019, 08:30 AM ET Company Participants Paul Arndt - Managing Director, LifeSci Advisors Allen Baharaff - Co-Founder, President, Chief Executive Officer Liat Hayardeny - Chief Scientific Officer ...
Galmed ( GLMD ) FY results : Revenues: $2M (+81.8%). More news on: Galmed Pharmaceuticals Ltd., Healthcare stocks news, Earnings news and commentary, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Galmed Pharmaceuticals Ltd. Company Name:
GLMD Stock Symbol:
NASDAQ Market:
Shares of PriceSmart, Inc. (NASDAQ: PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for...
Shares of Agenus Inc. (NASDAQ: AGEN) fell sharply during Monday’s session. Agenus disclosed a 1-for-20 reverse stock split of common stock. A...